Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 28;58(4):501-508.
doi: 10.2478/raon-2024-0060. eCollection 2024 Dec 1.

The initial results of MRI-TRUS fusion prostate biopsy in high volume tertiary center

Tomaz Smrkolj  1   2 , Milena Taskovska  1   2 , Iztok Ditz  1   2 , Klemen Cernelc  1 , Simon Hawlina  1   2
Affiliations

The initial results of MRI-TRUS fusion prostate biopsy in high volume tertiary center

Tomaz Smrkolj et al. Radiol Oncol. .

Abstract

Background: Multiparametric magnetic resonance imaging (mpMRI) is a prerequisite for targeted prostate biopsy. The aim of our study was to evaluate the performance and learning curve of the mpMRI-transrectal ultrasound (TRUS) software image fusion (MRI-TRUS fusion) biopsy (BX) process in the first year after its introduction in our urology department.

Patients and methods: MRI-TRUS fusion BX was performed in 293 patients with at least one Prostate Imaging-Reporting and Data System (PIRADS) ≥3 lesion. The proportion of patients and lesions with positive histopathologic result for prostate cancer (PCa) was analyzed. The learning curve for MRI-TRUS fusion BX was assessed at institutional and individual level. Positive BX lesions were further analyzed by PIRADS and Gleason scores.

Results: The proportion of patients with positive histopathologic results for targeted BX, systematic BX, and combined BX was 53.9%, 47.9%, and 63.5%, respectively. The chi-square test for the proportion of PCa positive patients showed no significant difference between the time-based patient groups at the institutional level and no significant difference between individual urologists. PIRADS score (p < 0.001), total PSA concentration (p = 0.05), prostate volume (p < 0.001) and number of cores per lesion (p = 0.034) were significant predictors of a positive histopathologic result in a lesion-based analysis. Clinically significant PCa (csPCa) was confirmed in 34.7% of the 412 BX lesions and 76.4% of the 187 positive PCa lesions.

Conclusions: MRI-TRUS fusion targeted BX significantly improves the overall rate of PCa detection compared with systematic BX alone. No steep learning curve was observed in our urologists. The proportion of lesions with clinically insignificant PCa was low, limiting overdiagnosis of PCa.

Keywords: complications; learning curve; prostate cancer; targeted prostate biopsy.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Gleason score of all positive biopsy (BX) lesions. Category »not defined« includes lesions with suspect cores for carcinoma, undefined Gleason score in invasive carcinoma and atypical small acinar proliferation (ASAP).
FIGURE 2.
FIGURE 2.
Gleason score of Prostate Imaging-Reporting and Data System (PIRADS) 3 positive biopsy (BX) lesions.
See this image and copyright information in PMC

References

    1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38–52. doi: 10.1016/j.eururo.2019.08.005. - DOI - PubMed
    1. Zadnik V, Gašljević G, Hočevar M, Jarm K, Pompe-Kirn V, Strojan P, Cancer in Slovenia 2019. Oncology Institute Ljubljana. Cancer Epidemiology and Registry. Cancer Registry of the Republic of Slovenia; 2022. pp. 1–65. [Internet]. [cited 2024 May 27]. Available at: https://www.onko-i.si/rrs .
    1. Cornford P, Tilki D, van den Bergh RCN, Briers E, Eberli D, De Meerleer M, EAU guidelines 2024. European Association of Urology; 2024. Prostate cancer. [Internet]. [cited 2024 May 27]. Available at: https://uroweb.org/guidelines/prostate-cancer .
    1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–16. doi: 10.1056/NEJM198710083171501. - DOI - PubMed
    1. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ. et al. Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis. Urology. 2003;61:274–6. doi: 10.1016/s0090-4295(02)02398-1. - DOI - PubMed